Royalty payments from Roche and J&J for various drugs, alongside Argenx's demand and the acquisition of Antares Pharma's Xyosted, were reported.
2 reports, 1 independent
Updated Aug 6
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Royalty payments from Roche and J&J for various drugs, alongside Argenx's demand and the acquisition of Antares Pharma's Xyosted, were reported.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Halozyme tracks patient usage of OCREVUS ZUNOVO and monitors Opdivo Qvantig sales and conversion rates.Sub-event
Multiple companies reported on royalty payments and acquisitions involving Roche, J&J, Argenx, and Antares Pharma.1 source
Keep exploring
The entities involved
-
Hoffmann-La Roche
Swiss healthcare company
-
Johnson & Johnson
U.S multinational medical devices, pharmaceutical and consumer packaged goods manufacturer
-
Halozyme Therapeutics
Nothing else this week.
-
Argenx
company in Ghent, Belgium
Nothing else this week.
Coverage
Newest first; wire copies grouped- ZacksHALO Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View Halozyme Therapeutics HALO reported second-quarter 2025 adjusted earnings of $1.54 per share, which comprehensively beat the Zacks Cons
- ZacksALNY Q2 Earnings Top Estimates on Higher Amvuttra Revenues, Stock Up Alnylam Pharmaceuticals, Inc. ALNY reported second-quarter 2025 earnings of 32 cents per share, in contrast to the Zacks Consensus